TABLE 2.
Sensitivities of tests for detection of antibodies to HIV-1 and HIV-2 with commercial seroconversion panelsa
| Panel | No. of days since first bleed | Determine HIV-1/2 result | PA result | Latex agglu-tination test result | S/COb
|
|
|---|---|---|---|---|---|---|
| Abbott HIV-1/2 | Gen Sys HIV-1/2 | |||||
| PRB928-01 | 0 | − | − | − | 0.2 | 0.3 |
| PRB928-02 | 111 | + | + | − | 7.8 | 0.3 |
| PRB928-03 | 120 | + | + | + | 15.1 | 1.9 |
| PRB928-04 | 125 | + | + | + | 15.6 | 2.5 |
| PRB928-05 | 130 | + | + | + | 16.4 | 3.6 |
| PRB929-01 | 0 | − | − | − | 0.2 | 0.1 |
| PRB929-02 | 4 | − | − | − | 0.2 | 0.1 |
| PRB929-03 | 14 | − | − | − | 0.2 | 0.1 |
| PRB929-04 | 18 | − | − | − | 0.2 | 0.1 |
| PRB929-05 | 21 | − | − | − | 0.9 | 0.1 |
| PRB929-06 | 25 | + | + | + | >16.3 | 0.1 |
| PRB929-07 | 28 | + | + | + | >16.3 | 1.2 |
| PRB930-01 | 0 | − | − | − | 0.1 | 0.2 |
| PRB930-02 | 3 | − | − | − | 0.1 | 0.2 |
| PRB930-03 | 7 | + | − | − | 10.2 | 0.3 |
| PRB930-04 | 10 | + | + | + | >18.3 | 2.2 |
| PRB931-01 | 0 | − | − | − | 0.1 | 0.1 |
| PRB931-02 | 2 | − | − | − | 0.1 | 0.1 |
| PRB931-03 | 7 | − | − | − | 0.1 | 0.1 |
| PRB931-04 | 9 | − | − | − | 0.1 | 0.1 |
| PRB931-05 | 15 | − | − | − | 0.1 | 0.1 |
| PRB931-06 | 28 | + | + | + | 6.0 | 0.4 |
| PRB931-07 | 33 | + | + | + | >18.7 | 1.1 |
| PRB931-08 | 35 | + | + | + | >18.7 | 1.9 |
| PRB931-09 | 42 | + | + | + | >18.7 | 4.0 |
a
Seroconversion panels were from Boston Biomedia Inc.
b
Data were provided by Boston Biomedica Inc. S/CO, specimen absorbance (optical density)-to-cutoff ratios. Samples with ratios of ≥1.0 are considered positive.